Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics, Inc. removed R. Erik Holmlin, Ph.D. as president and chief executive officer effective May 5, 2026, and he also resigned from the board. He will receive severance under his employment agreement and is expected to serve as an advisor/consultant during the transition.
The board appointed chairman Albert A. Luderer, Ph.D. as interim chief executive officer and interim principal financial officer, while he continues as board chair. Under an offer letter dated May 6, 2026, he will receive a $600,000 annual base salary, up to a $400,000 pro-rated 2026 incentive bonus, and a $4,000 monthly housing and travel stipend.
Christopher J. Twomey was named Lead Independent Director and joined the compensation committee. The company plans to conduct a search for a permanent CEO and stated it anticipates a seamless leadership transition without business disruption.
Bionano Genomics, Inc. is calling its 2026 Annual Meeting of Stockholders for May 14, 2026 at 10:00 a.m. Pacific Time, to be held exclusively online via live audio webcast at www.proxydocs.com/BNGO.
Stockholders will vote on electing two Class II directors to serve until the 2029 annual meeting, an advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board recommends voting “For” all three proposals. Stockholders of record as of March 19, 2026, when 11,091,615 shares of common stock were outstanding, are entitled to vote.
Bionano Genomics provides genome analysis solutions centered on optical genome mapping (OGM), nucleic acid purification, diagnostic services and VIA software. It focuses on structural variant detection in constitutional disease, cancer and cell and gene therapy research.
The company flags substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flows and a need for significant additional capital, with potential outcomes including curtailing operations or liquidation. As of June 30, 2025, non‑affiliate equity market value was about $12.2 million, and as of March 19, 2026 there were 11,092,000 common shares outstanding.
Bionano reports an installed base of 387 OGM systems at December 31, 2025 and annual flowcell sales of 30,171, slightly below 2024. It highlights recent milestones including new VIA and Solve software advances, deployment of the Stratys system, and establishment of Category I CPT codes and Medicare payment determinations for OGM in hematologic malignancies and constitutional genetic disorders.
Bionano Genomics reported Q4 2025 revenue of $8.0M, down 3% from Q4 2024, with gross margin improving to 43%. For full-year 2025, revenue was $28.5M, a 7% decline from 2024 as instrument and discontinued clinical services revenue fell, partly offset by higher consumables and software revenue.
Full-year gross margin rose sharply to 46% from 1%, and operating expenses dropped 55% to $46.5M, reducing net loss to $26.4M from $112.0M. The company ended 2025 with $29.6M in cash, equivalents, investments and restricted short-term investments and guided 2026 revenue to $30–33M, with Q1 2026 guidance of $6.5–6.7M.
Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a small tax-related share disposition. On the vesting of a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 18 shares of common stock at $1.10 per share to cover tax obligations, leaving Chaubey with 644 directly owned shares.
The Principal Accounting Officer of Bionano Genomics, Inc., Mark Adamchak, reported a small tax-related share disposition. On February 15, 2026, 3 shares of common stock were withheld by the company at $1.10 per share to cover his tax obligations on a restricted stock unit (RSU) award that vested on that date. After this withholding, he directly owned 260 shares. This was an administrative tax-withholding disposition, not an open-market sale.
Bionano Genomics reported an insider equity transaction involving its General Counsel, Jonathan V. Dixon. On February 15, 2026, 6 shares of common stock were withheld by the company to cover tax obligations tied to a restricted stock unit award vesting, at a price of $1.10 per share. After this tax-withholding disposition, Dixon directly owns 263 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. chief operating officer Mark Oldakowski reported an automatic share disposition related to tax withholding. On shares that vested from a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 20 shares of common stock on February 15, 2026 to cover his tax obligations, at an indicated value of $1.10 per share. After this tax-withholding disposition, Oldakowski directly owned 895 shares of Bionano Genomics common stock. This was not an open-market buy or sell order, but a routine settlement mechanism tied to equity compensation.
Bionano Genomics President and CEO R. Erik Holmlin reported a small tax-related share disposition. On the settlement of a restricted stock unit (RSU) award that vested on February 15, 2026, the issuer withheld 51 shares of common stock at $1.10 per share to cover his tax obligations, rather than selling them on the open market. After this withholding transaction, he directly holds 1,657 shares of Bionano Genomics common stock.